Search filters
Filters
Clear All

Phase

  • 33
  • 94
  • 1
  • 80
  • 37
  • 1
  • 114
  • 383
  • 176
  • 13
  • 19
  • 351
  • 378
  • 5
  • 1
  • 382

Found 383 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer

UPCC 16517: A Phase 1 First-in-Human Open-Label Dose Escalation Study of JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Subjects with Advanced Non-Small Cell Lung Cancer

99 years or below
All genders
Phase 1
The purpose of this study is to see if JNJ-61186372 is safe and useful for treating patients with advanced, metastatic, non-small cell lung cancer (NSCLC).
Learn More
A Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Study of Osimertinib with or without Platinum Plus Pemetrexed Chemotherapy as First-line Treatment in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation- Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer

18 years - 99 years
All genders
Phase 3
Interventional
The purpose of this study is to try to find out if an experimental combination of an oral medication called osimertinib when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of non-small cell lung cancer (NSCLC). Eligible subjects will be adult subjects with …
Learn More
EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma

18 years - 99 years
All genders
Phase 3
This phase II/III trial studies the usefulness of treatment with nivolumab and ipilimumab in addition to standard of care chemotherapy and radiation therapy in patients with esophageal and gastroesophageal junction adenocarcinoma who are undergoing surgery. This trial is open to Penn Medicine's Abramson Cancer Center patients only. Please contact the …
Learn More
A Phase III Randomized Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Sqamous Cell Carcinoma

A Phase III Randomized Double-Blind Placebo-Controlled Study of Atezolizumab With or Without Tiragolumab (Anti-Tigit Antibody) in Patients with Unresectable Locally Advanced Esophageal Sqamous Cell Carcinoma

99 years or below
All genders
The purpose of this study is to compare the effects of atezolizumab plus tiragolumab versus atezolizumab plus placebo or double placebo on subjects with esophageal cancer who have had at least 2 cycles of chemoradiotherapy without progression of their disease. Subjects with unresectable, locally advanced esophageal cancer will receive either …
Learn More

UPCC 01122 A Randomized Phase II Trial of Adjuvant Trastuzumab Emtansine (T-DM1) Followed by Subcutaneous Trastuzumab Versus Paclitaxel in Combination with Subcutaneous Trastuzumab for Stage I HER2-positive Breast Cancer (ATEMPT 2.0)

99 years or below
All genders
Phase 2
Please refer to Protocol Section 1 (Objectives) Please refer to Protocol Section 13.1 (Study Design/Endpoints). Please refer to Protocol Section 13.1 (Study Design/Endpoints).
Learn More
UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

UPCC 01617: A Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody APX005M Administered in Combination with Nivolumab in Subjects with Non-small Cell Lung Cancer and Subjects with Metastatic Melanoma

99 years or below
All genders
Phase 2
Request for collaborative review: WIRB serving as IRB of record.
Learn More

EA5163/S1709 INSIGNA: A Randomized Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous NonSmall Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNaturedriven Analysis

99 years or below
All genders
This study is being done to answer the following questions: Does starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, result in a significant improvement in overall survival (OS) (time being alive) for patients with your type of cancer? Does additional treatment …
Learn More

UPCC 09922 A Phase 1 Open-label Multicenter Dose-ranging Study to Investigate Safety and Tolerability Efficacy Pharmacokinetics Pharmacodynamics and Immunogenicity of MT-6402 in Subjects with Advanced Solid Cancer That Expresses PD-L1

99 years or below
All genders
Phase 1
Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints). Please refer to Protocol Section 3 (Objectives and Endpoints).
Learn More
A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC

A pilot study to determine the feasibility of using plasma to detect mutations in patients with Stage II-III NSCLC

18 years - 99 years
All genders
This study will increase our ability to detect mutations in Stage II-III Non Small Cell Lung Cancer patients.
Learn More

UPCC 16122 A Phase II Multicentre Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer (OlympiaN)

99 years or below
All genders
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems.
Learn More
321 - 330 of 383